Anti-atherogenic effects of fibrates in type 2 diabetes
<p>Abstract</p> <p>Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins reduces the...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2001-09-01
|
Series: | Current Controlled Trials in Cardiovascular Medicine |
Subjects: | |
Online Access: | http://cvm.controlled-trials.com/content/2/5/218 |